Abeona Therapeutics Inc [ABEO] stock prices are up 8.02% to $7.54 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ABEO shares have gain 7.56% over the last week, with a monthly amount glided 58.40%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, February 2024, Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
From an analyst’s perspective:
Abeona Therapeutics Inc [NASDAQ: ABEO] stock has seen the most recent analyst activity on November 11, 2020, when Cantor Fitzgerald upgraded its rating to a Overweight but kept the price target unchanged to $4 for it. Previously, B. Riley FBR started tracking the stock with Buy rating on September 18, 2020, and set its price target to $5. On February 10, 2020, SVB Leerink initiated with a Outperform rating and assigned a price target of $6 on the stock. Maxim Group downgraded its rating to a Hold. Cantor Fitzgerald downgraded its rating to Neutral for this stock on August 12, 2019, and downed its price target to $2. In a note dated July 26, 2019, Mizuho downgraded an Neutral rating on this stock and revised its target price from $17 to $4.
The stock price of Abeona Therapeutics Inc [ABEO] has been fluctuating between $2.19 and $7.50 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Abeona Therapeutics Inc [NASDAQ: ABEO] shares were valued at $7.54 at the most recent close of the market. An investor can expect a potential drop of -20.42% based on the average ABEO price forecast.
Analyzing the ABEO fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.08 points at the first support level, and at 6.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.85, and for the 2nd resistance point, it is at 8.16.
Abeona Therapeutics Inc [ABEO] reported earnings per share of -$0.48 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.53/share, meaning a difference of $0.05 and a surprise factor of 9.40%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.92 per share as compared to estimates of -$0.68 per share, a difference of -$0.24 representing a surprise of -35.30%.
Ratios To Look Out For
It’s worth pointing out that Abeona Therapeutics Inc [NASDAQ:ABEO]’s Current Ratio is 6.81. In addition, the Quick Ratio stands at 6.81 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 52.32, the price to book ratio is 8.46.
Transactions by insiders
Recent insider trading involved Seshadri Vishwas, Chief Executive Officer, that happened on Feb 06 when 20000.0 shares were purchased. Director, Alvino Mark completed a deal on Jan 17 to sell 7084.0 shares. Meanwhile, Chief Executive Officer Seshadri Vishwas bought 20000.0 shares on Sep 27.
